The 5 most recent market catalysts affecting $CTS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 55
Barrington Research Initiates Coverage On CTS with Outperform Rating, Announces Price Target of $80
Barrington Research has initiated coverage on CTS, assigning an Outperform rating and an $80 price target. This event is significant for CTS as new analyst coverage, especially wit…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 55
Lake Street Initiates Coverage On CTS with Buy Rating, Announces Price Target of $67
Lake Street analyst Jaeson Schmidt initiated coverage on CTS with a 'Buy' rating and set a price target of $67. This event is a positive catalyst for CTS as new analyst coverage, e…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 55
CTS Expands Distribution Of Current Sensing Solutions To Authorized Partners, Targeting High-Growth Non-Automotive Markets
CTS Corporation is expanding the distribution of its current sensing solutions through its authorized partners, specifically targeting high-growth non-automotive markets such as da…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
CTS shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY2026 adjusted EPS and FY2026 sales guidance above estimates.
This headline represents a significant positive corporate catalyst for CTS. The combination of beating current quarter expectations and raising future guidance signals strong under…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 92
CTS Q2 Adj. EPS $0.74 Beats $0.61 Estimate, Sales $144.780M Beat $143.428M Estimate
CTS announced its second-quarter earnings, reporting adjusted EPS of $0.74, significantly beating the analyst consensus of $0.61, and sales of $144.780 million, also surpassing the…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.